Literature DB >> 8806246

Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group.

P Pezzotti1, A N Phillips, M Dorrucci, A C Lepri, N Galai, D Vlahov, G Rezza.   

Abstract

OBJECTIVES: To determine whether rate of development of AIDS is affected by category of exposure to HIV and whether the more rapid development found in older subjects persists for each exposure category.
DESIGN: Longitudinal study of people with known date of seroconversion to HIV.
SETTING: 16 HIV treatment centres throughout Italy.
SUBJECTS: 1199 people infected with HIV through use of injected drugs, homosexual sex, or heterosexual sex. MAIN OUTCOME MEASURES: AIDS as defined by 1987 definition of Centers for Disease Control (including and excluding neoplasms) and by 1993 European definition.
RESULTS: 225 subjects (18.8%) progressed to AIDS (Centers for Disease Control 1987 definition) during median follow up of 5.8 years. Univariate analyses showed more rapid progression to AIDS for older subjects compared with younger subjects and for homosexual men compared with other exposure categories. The age effect was of similar size in each exposure category and in men and women. In a bivariate model with age and exposure categories simultaneously included as covariates, differences by exposure category disappeared for use of injected drugs and heterosexual sex compared with homosexual sex (relative hazards 1.02 (95% confidence interval 0.71 to 1.45) and 1.07 (0.70 to 1.64) respectively), while the age effect remained (relative hazard 1.55 (1.32 to 1.83) for 10 year increase in age). Analyses using the other definitions for AIDS did not appreciably change these results.
CONCLUSIONS: There was no evidence of differences in rate of development of AIDS by exposure category, while there was a strong tendency for more rapid development in older subjects for all three groups. This supports the view that external cofactors do not play major role in AIDS pathogenesis but that age is of fundamental importance.

Entities:  

Mesh:

Year:  1996        PMID: 8806246      PMCID: PMC2352019          DOI: 10.1136/bmj.313.7057.583

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

1.  Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals.

Authors:  A B Mariotto; S Mariotti; P Pezzotti; G Rezza; A Verdecchia
Journal:  Am J Epidemiol       Date:  1992-02-15       Impact factor: 4.897

2.  Influence of gender, age, and transmission category on the progression from HIV seroconversion to AIDS.

Authors:  P Pezzotti; G Rezza; A Lazzarin; G Angarano; A Sinicco; F Aiuti; R Zerboni; B Salassa; S Gafà; R Pristerà
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

3.  Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users.

Authors:  G H Mientjes; F Miedema; E J van Ameijden; A A van den Hoek; P T Schellekens; M T Roos; R A Coutinho
Journal:  AIDS       Date:  1991-01       Impact factor: 4.177

4.  Risk of developing AIDS in HIV-infected cohorts of hemophilic and homosexual men.

Authors:  J Jason; K J Lui; M V Ragni; N A Hessol; W W Darrow
Journal:  JAMA       Date:  1989-02-03       Impact factor: 56.272

5.  Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users.

Authors:  J B Margolick; A Muñoz; D Vlahov; J Astemborski; L Solomon; X Y He; K E Nelson; A J Saah
Journal:  Arch Intern Med       Date:  1994-04-25

6.  Expanded European AIDS case definition.

Authors:  R Ancelle-Park
Journal:  Lancet       Date:  1993-02-13       Impact factor: 79.321

7.  Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures.

Authors:  P K Peterson; B M Sharp; G Gekker; P S Portoghese; K Sannerud; H H Balfour
Journal:  AIDS       Date:  1990-09       Impact factor: 4.177

8.  AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters.

Authors:  R J Biggar
Journal:  AIDS       Date:  1990-11       Impact factor: 4.177

9.  Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.

Authors:  J Giesecke; G Scalia-Tomba; O Berglund; E Berntorp; S Schulman; L Stigendal
Journal:  BMJ       Date:  1988-07-09

10.  Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis.

Authors:  M Bofill; G Janossy; C A Lee; D MacDonald-Burns; A N Phillips; C Sabin; A Timms; M A Johnson; P B Kernoff
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

View more
  15 in total

1.  Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans.

Authors:  D S Zingmond; N S Wenger; S Crystal; G F Joyce; H Liu; U Sambamoorthi; L A Lillard; A A Leibowitz; M F Shapiro; S A Bozzette
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

2.  Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection.

Authors:  Maile Y Karris; Yu-ting Kao; Derek Patel; Matthew Dawson; Steven P Woods; Florin Vaida; Celsa Spina; Douglas Richman; Susan Little; Davey M Smith
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

3.  Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD).

Authors:  K Petoumenos; M T van Leuwen; C M Vajdic; I Woolley; J Chuah; D J Templeton; A E Grulich; M G Law
Journal:  HIV Med       Date:  2012-08-30       Impact factor: 3.180

4.  HIV seroconversion interval and demographic characteristics: no evidence of selection bias.

Authors:  P Vanhems; R Allard; M Dhénain; C Chidiac; D Peyramond; J L Touraine; C Trépo; J Ritter; J Fabry
Journal:  Sex Transm Infect       Date:  2001-12       Impact factor: 3.519

5.  Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in Women.

Authors: 
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

6.  Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults.

Authors:  Hyun J Lim; Alphonse Okwera; Harriet Mayanja-Kizza; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen
Journal:  HIV Clin Trials       Date:  2006 Jul-Aug

7.  Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.

Authors:  Aaron M Kipp; Andrew J Desruisseau; Han-Zhu Qian
Journal:  J Subst Abuse Treat       Date:  2011-02-24

8.  Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men.

Authors:  C M Lyles; N M Graham; J Astemborski; D Vlahov; J B Margolick; A J Saah; H Farzadegan
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

9.  Methods for estimating HIV prevalence: A comparison of extrapolation from surveys on infection rate and risk behaviour with back-calculation for the Netherlands.

Authors:  H Houweling; S H Heisterkamp; L G Wiessing; R A Coutinho; J K van Wijngaarden; H J Jager
Journal:  Eur J Epidemiol       Date:  1998-10       Impact factor: 8.082

10.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.